A recent study has shown high levels of serum CXCL-8, CXCL-9 and CXCL-10 are associated with hepatic flare. However, the pathogene-sis of HBV reactivation in HBeAg negative chronic hepatitis B infection is not clear. In this study, we evaluated levels of serum cytokines and chemokines including IFN-α, PD-0332991 ic50 IL-1b, TNF-a, IL-6, IL-8, IL-10, CCL-2, CCL-3, CXCL-9, and CXCL-10 in HBeAg negative chronic hepatitis B patients with a range of ALT values. METHODS: Eighty five serum samples of chronic hepatitis B HBeAg negative patients with different levels of abnormal
ALT (1 sample/patient, all ALT>70 IU/L) were studied. In these patients/samples, 39 were during HBV reactivation while the rest 46 were not. Serum cytokines/chemokines were analyzed using Affymetrix 10-plex human cytokine kit and Bio-Plex MAGPIX system. Cytokine/chemokine concentrations were calculated using Bio-Plex Manager 6.1. HBV DNA levels were quantified using serum extracted DNA as template and real time PCR with a VQC standard panel. Statistical analyses were carried out using SPSS v17. Data were presented as mean ± SE. RESULTS: Correlation analysis of all variables
showed a positive correlation between CXCL9 and ALT levels (Pearson’s r=0.37, p<0.001), and between CXCL9 and HBV DNA levels (Pearson's r=0.33, p<0.001). Whereas, other cytokines/ chemokines were not correlate with ALT and HBV DNA levels in HBeAg negative patients. In addition, the ALT and HBV DNA levels in samples of during HBV reactivation Compound Library clinical trial were significantly higher than those without reactivation (478.5 ± 97.4 vs. 161.6 ± 25.9 IU/L, p=0.003; and 6.2 ± 0.19 vs. 5.0 ± 0.21 Log10 IU/mL, p<0.001 respectively) Molecular motor as were the CXCL9 levels (249.3 ± 39.9 vs. 116.2 ± 24.4 pg/mL, p=0.005). There was no significant difference in levels of other cytokines/chemokines between samples during and non-during HBV reactivation. CONCLUSION: CXCL9 is correlated with ALT and HBV DNA levels in HBeAg negative patients. HBeAg negative patients have higher serum CXCL9 levels during HBV reactivation. CXCL9 seems to be not just important in hepatic
flares but also in milder forms of abnormal ALT elevation. CXCL9 may play an important role in HBV reactivation in HBeAg negative chronic hepatitis B infection. Disclosures: Seng Gee Lim – Advisory Committees or Review Panels: Bristol-Myers Squibb, Achillon Pharmaceuticals, Pfizer Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Merck Sharp and Dohme Pharmaceuticals, Vertex Pharmaceuticals, Boehringer-Ingelheim, Gilead Pharmaceuticals, Roche Pharmaceuticals, Tobira Pharmaceuticals; Speaking and Teaching: GlaxoSmithKline, Bristol-Myers Squibb, Merck Sharp and Dohme Pharmaceuticals, Boehring-er-Ingelheim, Gilead Pharmaceuticals, Novartis Pharmaceuticals The following people have nothing to disclose: Yan Cheng, Veonice Bijin Au, John E.